İntrakraniyal Tümörlerde Moleküler Görüntüleme

Kaynakça (10)

1. . Kadekaro M, Vance WH, Terrell ML, Gary H Jr, Eisenberg HM Sokoloff L. Effects of antidromic stimulation of the ventral root on glucose utilization in the ventral horn of the spinal cord in the rat. Proc Natl Acad Sci U S A 1987
2. [CrossRef] [2]. Di Chiro, G, DeLaPaz, RL, Brooks, RA, Sokoloff, L, Kornblith, PL, Smith, BH, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982
3. [CrossRef] [3]. Hustinx, R, Smith, RJ, Benard, F, Bhatnagar, A Alavi, A. Can the standardized uptake value characterize primary brain tumors on FDG-PET? Eur J Nucl Med 1999
4. . Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDGPET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol 2015 Aug 4. Pii: nov 148 [Epub ahead of print] [5]. Manabe O, Hattori N, Yamaguchi S, Hirata K, Kobayashi K, Terasaka S, et al. Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging. Eur J Nucl Med Mol Imaging 2015
5. [CrossRef] [6]. Kosaka N, Tsuchida T, Uematsu H, Kimura H, Okazawa H, Itoh H. 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol 2008
6. W365-9. [7]. Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold, SC. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 1992
7. . Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt-Wolf IG, Matthies A, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 2006
8. [CrossRef] [9]. Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, Rostomily RC, et al. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 2002
9. . Charnley N, West CM, Barnett CM, Brock C, Bydder GM, Glaser M, et al. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys 2006
10. [CrossRef] [11]. Bergström M, Lundqvist H, Ericson K, Lilja A, Johnstrom P, Langstrom B, et al. Comparison of the accum